On the call they said not to expect meaningful revenue till Q4 still I like the aggressive nature of the new CEO.
The guidance for the year increased to 125-130 is still pretty low IMO it would imply 75-80M for Q3+Q4 which is basically no growth given the number of patients now on drug. Granted summer months may have slower uptake perhaps some more missed doses but I think they are (continuing to be) conservative.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.